首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Deletion of proapoptotic Puma selectively protects hematopoietic stem and progenitor cells against high-dose radiation.
【24h】

Deletion of proapoptotic Puma selectively protects hematopoietic stem and progenitor cells against high-dose radiation.

机译:促凋亡Puma的删除选择性地保护造血干细胞和祖细胞免受高剂量辐射。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Bone marrow injury is a major adverse side effect of radiation and chemotherapy. Attempts to limit such damage are warranted, but their success requires a better understanding of how radiation and anticancer drugs harm the bone marrow. Here, we report one pivotal role of the BH3-only protein Puma in the radiosensitivity of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). Puma deficiency in mice confers resistance to high-dose radiation in a hematopoietic cell-autonomous manner. Unexpectedly, loss of one Puma allele is sufficient to confer mice radioresistance. Interestingly, null mutation in Puma protects both primitive and differentiated hematopoietic cells from damage caused by low-dose radiation but selectively protects HSCs and HPCs against high-dose radiation, thereby accelerating hematopoietic regeneration. Consistent with these findings, Puma is required for radiation-induced apoptosis in HSCs and HPCs, and Puma is selectively induced by irradiation in primitive hematopoietic cells, and this induction is impaired in Puma-heterozygous cells. Together, our data indicate that selective targeting of p53 downstream apoptotic targets may represent a novel strategy to protecting HSCs and HPCs in patients undergoing intensive cancer radiotherapy and chemotherapy.
机译:骨髓损伤是放疗和化疗的主要不良副作用。试图限制这种损害是有必要的,但是它们的成功需要更好地了解放射线和抗癌药如何伤害骨髓。在这里,我们报告仅BH3蛋白美洲狮在造血干细胞(HSCs)和造血祖细胞(HPCs)的放射敏感性中的关键作用。小鼠体内的彪马缺乏症以造血细胞自主方式赋予对大剂量辐射的抗性。出乎意料的是,一个彪马等位基因的缺失足以赋予小鼠抗辐射性。有趣的是,Puma中的无效突变可以保护原始和分化的造血细胞免受低剂量辐射引起的损害,但可以选择性地保护HSC和HPC免受高剂量辐射的侵害,从而加速造血细胞的再生。与这些发现一致,在辐射诱导的HSC和HPC中凋亡需要Puma,并且Puma在原始造血细胞中被辐射选择性诱导,并且这种诱导在Puma-heterozygous细胞中受损。总之,我们的数据表明,选择性靶向靶向p53下游凋亡靶标可能代表一种保护正在接受重度癌症放疗和化疗的患者HSCs和HPCs的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号